Holen Sie sich die Stockscreener-App
1.41
6.00%
-0.09
Schlusskurs vom Vortag:
$1.50
Offen:
$1.47
24-Stunden-Volumen:
3,777
Relative Volume:
0.49
Marktkapitalisierung:
$8.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.67M
KGV:
-0.25
EPS:
-5.64
Netto-Cashflow:
$-20.41M
1W Leistung:
-9.03%
1M Leistung:
-18.02%
6M Leistung:
-35.32%
1J Leistung:
-41.74%
1-Tages-Spanne:
$1.43
$1.52
1-Wochen-Bereich:
$1.43
$1.58
52-Wochen-Spanne:
$0.8401
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Eterna Therapeutics Inc
Sektor
Branche
Telefon
(212) 582-1199
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Eterna Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World
Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com UK
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024 - MSN
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024 - InvestorPlace
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics - Quantisnow
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared ... - Quantisnow
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index - Quantisnow
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Quantisnow
Brooklyn ImmunoTherapeutics Reports Inducement Grants - Quantisnow
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement - Quantisnow
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's Intraday SessionConcord Medical Services (NYSE:CCM), Bio-Path - Benzinga
12 Health Care Stocks Moving In Monday's Intraday SessionConcord Medical Services (NYSE:CCM), Bio-Path Hldgs ... - Benzinga
Investor's Delight: Eterna Therapeutics Inc (ERNA) Closes Weak at 1.83, Down -1.08 – DWinneX - The Dwinnex
Eterna Therapeutics (NASDAQ:ERNA) Stock Price Down 5.4% - Defense World
Eterna Therapeutics (NASDAQ:ERNA) & Adicet Bio (NASDAQ:ACET) Critical Analysis - Defense World
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout ... - GlobeNewswire
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout ... - WICZ
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases - GlobeNewswire Inc.
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potenti - StockTitan
Eterna Therapeutics enhances board with stem cell expert - Investing.com
Eterna Therapeutics enhances board with stem cell expert - Investing.com South Africa
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewswire
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewswire Inc.
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - Yahoo Finance
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC ... - Yahoo Finance UK
Eterna Therapeutics faces Nasdaq noncompliance issue - Investing.com India
Why Is Kopin (KOPN) Stock Down 15% Today? - InvestorPlace
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - Yahoo Finance
CERo Therapeutics Hldgs Stock (NASDAQ:CERO), Quotes and News Summary - Benzinga
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule ... - Yahoo Finance
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO - Yahoo Finance Australia
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Yahoo Finance
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - Yahoo Finance
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - Business Wire
Finanzdaten der Eterna Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.26%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):